Scarica l'app Stockscreener
5.72
1.42%
0.08
Dopo l'orario di chiusura:
5.72
Seres Therapeutics Inc Borsa (MCRB) Ultime notizie
Seres Therapeutics to Participate in H.C. Wainwright 28th Annual Global Investment Conference - Stock Titan
Seres Therapeutics Inc. (MCRB) Peer Comparison – Compare with Others - valueresearchonline.com
Seres Therapeutics Inc. (MCRB) Shareholding Pattern – Promoters, FIIs & DIIs - valueresearchonline.com
Seres (MCRB) Earnings Report: The Available Earnings Metric Delivers a Beat; Post-Report: The Stock Ends Up 2.19%Profit Growth Outlook - vinanet.vn
Seres Therapeutics, Inc. SEC Filing (Aug 24, 2026) - Stock Titan
Should I Buy MCRB? MCRB 2026 AnalysisIntellectia AI™ - Intellectia AI
Seres Therapeutics director Eric Shaff sells $1,196 in shares By Investing.com - Investing.com South Africa
Seres Therapeutics director Eric Shaff sells $1,196 in shares - Investing.com
Seres Therapeutics (NASDAQ: MCRB) COO sells 64 shares after 181 RSUs vest - Stock Titan
Seres Therapeutics (MCRB) director sale tied to RSU tax plan - Stock Titan
Microbiome Therapeutics Market Size, Share | Forecast [2034] - Fortune Business Insights
Seres Therapeutics, Inc. Revenue Breakdown – NASDAQ:MCRB - TradingView
Seres TherapeuticsMay Offer Up To $300 Million Of Securities - TradingView
MCRB Stock Declines As Seres Therapeutics Pauses SER-155 Phase 2 Study And Shrinks Headcount By 30% - Stocktwits
Seres Therapeutics Inc (MCRB) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
CCORF Maintains Seres Therapeutics(MCRB.US) With Buy Rating, Maintains Target Price $22 - Moomoo
Seres Therapeutics exits more Cambridge real estate early - The Business Journals
Seres Therapeutics Inc earnings beat by $2.77, revenue topped estimates - Investing.com
Seres Therapeutics Q2 Operating Income USD -2 - Moomoo
Seres Therapeutics, Inc. 2Q 2026: Revenue $0.736M, Net income $4.581M, EPS $0.47— 10-Q Summary - TradingView
Seres Therapeutics, Inc. reports results for the quarter ended June 30Earnings Summary - TradingView
Seres Therapeutics (MCRB) Q2 Revenue Surpasses Expectations Amid Clinical Progress - GuruFocus
Seres Therapeutics Reports Second Quarter 2026 Financial Results and Provides Business Updates, Including Further Action to Reduce Ongoing Facilities Costs - The Manila Times
Seres Therapeutics Q2 Net Income Reaches $4.6 Million - Quiver Quantitative
Seres Therapeutics: Q2 Earnings Snapshot - marketscreener.com
Seres Therapeutics reports Q2 2026 net income of $4.6M, cash $15.6M, advances SER-155 clinical plans - TradingView
MCRB: Returned to profitability in Q2 2026, driven by VOWST sale gains and SER-155 trial success - TradingView
Q2 2026 financial results released as Seres Therapeutics advances business update - Traders Union
Seres Therapeutics Reports Second Quarter 2026 Financial - GlobeNewswire
Seres Therapeutics Streamlines Cambridge Operations with Lease Changes - TipRanks
MCRB Q2'26 Earnings: EPS estimate is (2.19) USD - TradingView
Seres Therapeutics Inc expected to post a loss of $2.18 a shareEarnings Preview - TradingView
MCRB Q2'26 Earnings: revenue estimate is 179.00K USD - TradingView
Seres Therapeutics Inc (MCRB) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
Seres Therapeutics Inc (MCRB) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
Seres Therapeutics (MCRB) Slides Slightly as Stock Tests Key Support LevelCTA Positioning - vinanet.vn
TradingKey - TradingKey
Seres Therapeutics Inc (MCRB) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
Seres Therapeutics Inc Revenue Breakdown – BX:MCRB - TradingView
Seres Therapeutics Inc (MCRB) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
MCRB|Seres Therapeutics Inc|Price:4.980|Chg%:-0.250 - TradingKey
Seres Therapeutics Inc (MCRB) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
Seres Therapeutics (MCRB) H.C. Wainwright 4th Annual BioConnect Investor Conference summary - Quartr
Seres Therapeutics Slides 5.25% as MCRB Approaches Critical Support at $4.80Social Sentiment - dars.gov.et
Seres Therapeutics (MCRB) Plunges 9%: Key Support and Resistance Levels in FocusIsland Reversal - dars.gov.et
Form 4 Seres Therapeutics Inc For: 10 July By Investing.com - Investing.com South Africa
Seres Therapeutics (MCRB) awards director Eric Shaff 6,500 stock options at $7.14 - Stock Titan
Seres Therapeutics (MCRB) awards 6,500-share stock option grant to director Dere - Stock Titan
[Form 4] Seres Therapeutics, Inc. Insider Trading Activity - Stock Titan
Seres Therapeutics (MCRB) awards 6,500 stock options to director Claire Fraser - Stock Titan
Seres Therapeutics (MCRB) awards 6,500 stock options to director Robert L. Rosiello - Stock Titan
Seres Therapeutics (MCRB) awards 6,500 stock options to director Stephen Berenson - Stock Titan
Seres Therapeutics’ SER-155 Posts 80% Response in Cancer Immunotherapy GI Toxicity Study - Yahoo Finance
Seres Therapeutics (MCRB) awards 50,000 stock options to director-officer - Stock Titan
Seres Therapeutics, Inc. Amends and Restates 2025 Incentive Award Plan in SEC 8-K Filing - Minichart
Seres Therapeutics Shareholders Approve Directors and Executive Pay - TipRanks
Seres Therapeutics (NASDAQ: MCRB) investors back 900,000-share 2025 incentive plan increase - Stock Titan
Seres Therapeutics (MCRB) Q4 2025 earnings summary - Quartr
Why Is Seres Therapeutics Stock Falling Today?Seres Therapeutics (NASDAQ:MCRB) - Benzinga
Seres Therapeutics, Inc. (MCRB) Discusses Promising SER-155 Clinical Trial Results for Immune Checkpoint Inhibitor Related AndropilatisSlideshow (NASDAQ:MCRB) 2026-07-08 - Seeking Alpha
Seres Therapeutics reports positive early SER-155 data - grafa.com
Seres’ SER-155 takes on immune checkpoint inhibitor-related enterocolitis - BioWorld News
MCRB: All proposals, including director elections and incentive plan amendment, were approved - TradingView
Seres reports trial results for experimental colitis treatment - Investing.com
0.86%
0.31%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):